V
Volkmar Henschel
Researcher at Hoffmann-La Roche
Publications - 36
Citations - 2742
Volkmar Henschel is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Atezolizumab & Population. The author has an hindex of 18, co-authored 35 publications receiving 1988 citations. Previous affiliations of Volkmar Henschel include Heidelberg University & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid,Hope S. Rugo,Sylvia Adams,Andreas Schneeweiss,Carlos H. Barrios,Hiroji Iwata,Véronique Diéras,Volkmar Henschel,Luciana Molinero,Stephen Y. Chui,Vidya Maiya,Amreen Husain,Eric P. Winer,Sherene Loi,Leisha A. Emens,IMpassion Investigators +15 more
TL;DR: The prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-negative breast cancer occurred.
Journal ArticleDOI
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw,Leena Gandhi,Shirish M. Gadgeel,Gregory J. Riely,Jeremy Cetnar,Howard West,D. Ross Camidge,Mark A. Socinski,Alberto Chiappori,Tarek Mekhail,Bo H. Chao,Hossein Borghaei,Kathryn A. Gold,Ali Zeaiter,Walter Bordogna,Bogdana Balas,Oscar Puig,Volkmar Henschel,Sai-Hong Ignatius Ou +18 more
TL;DR: Alectinib showed clinical activity and was well tolerated in patients with ALK-positive NSCLC who had progressed on crizotinib and could be a suitable treatment for patients with AlK- positive disease who have progressed oncrizotin ib.
Journal ArticleDOI
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron,Julia Brown,Rebecca Dent,Christian Jackisch,John R. Mackey,Xavier Pivot,Guenther G. Steger,Thomas M. Suter,Masakazu Toi,Mahesh K. B. Parmar,Rita Laeufle,Young-Hyuck Im,Gilles Romieu,Vernon Harvey,Oleg Lipatov,Tadeusz Pienkowski,Paul Cottu,A. Chan,Seock-Ah Im,Peter Hall,Lida Bubuteishvili-Pacaud,Volkmar Henschel,Regula Deurloo,Celine Pallaud,Richard Bell +24 more
TL;DR: Bvacizumab cannot be recommended as adjuvant treatment in unselected patients with triple-negative breast cancer and exploratory biomarker assessment suggests that patients with high pre-treatment plasma VEGFR-2 might benefit from the addition of bevaczumab.
Journal ArticleDOI
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Leisha A. Emens,Sylvia Adams,Carlos H. Barrios,Véronique Diéras,H. Iwata,Sherene Loi,Hope S. Rugo,Andreas Schneeweiss,EP Winer,Sheetal Patel,Volkmar Henschel,A. Swat,M. Kaul,Luciana Molinero,S.Y. Chui,Peter Schmid +15 more
TL;DR: The final overall survival (OS) and safety of that study as per the prespecified analysis plan was reported in this article, where patients were randomized to nP 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (AÂ+ nP) or placebo (PÂ + nP; days 1 and 15), until progression or unacceptable toxicity.
Proceedings ArticleDOI
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
DJ Slamon,Sandra M. Swain,Marc Buyse,M. Martin,Charles E. Geyer,Y-H Im,Tadeusz Pienkowski,S-B Kim,Nicholas J. Robert,Günther G. Steger,J.P. Crown,S. Verma,Wolfgang Eiermann,Joseph P. Costantino,S-A Im,Eleftherios P. Mamounas,Lee S. Schwartzberg,Ahg Paterson,John R. Mackey,Louise Provencher,Michael F. Press,M. Thirlwell,V. Bee-Munteanu,Volkmar Henschel,A Crepelle-Flechais,Norman Wolmark +25 more
TL;DR: A randomized, phase 3, open-label study evaluating the addition of B to 2 different H-chemo regimens to assess the impact of VEGF-A blockade on residual or micrometastatic disease in the adjuvant setting.